- Raw materials
- Barbiturates
- Ocinaplon
Ocinaplon API Manufacturers & Suppliers
0 verified results
All Ocinaplon data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ocinaplon | CAS No: 96604-21-6 | GMP-certified suppliers
A medication that is being investigated for managing anxiety disorders by providing central nervous system depressant and sedative effects in nonbenzodiazepine hypnotic therapy.
Therapeutic categories
Primary indications
- Investigated for use/treatment in anxiety disorders
Product Snapshot
- Ocinaplon is an oral small molecule formulation
- It is primarily investigated for use in anxiety disorders
- The compound is currently in an investigational status and not yet approved by regulatory authorities
Clinical Overview
Pharmacologically, ocinaplon is categorized as a central nervous system depressant with hypnotic properties. It falls under the broader drug categories of nonbenzodiazepine hypnotics and sedatives. While specific pharmacodynamic and mechanistic details have not been fully disclosed, its chemical framework suggests potential activity at central nervous system receptor sites involved in anxiolytic and sedative effects.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for ocinaplon remain limited in publicly available data due to its investigational status. There is no comprehensive information on its bioavailability, metabolic pathways, elimination half-life, or excretion routes at this time.
Safety and toxicity profiles have yet to be conclusively established. Given its pharmacological class and investigational status, ocinaplon’s tolerability, adverse effects, and potential drug interactions require further clinical investigation before authorizing wider therapeutic use.
Ocinaplon is not currently marketed under any approved brand names and remains under evaluation in clinical development. Its investigational nature implies non-approval by major regulatory agencies, restricting its clinical use to controlled research settings.
For pharmaceutical development and API sourcing, attention should be given to the compound’s complex heterocyclic structure which may present synthetic challenges. Ensuring high purity and adherence to stringent quality standards is critical, as impurities or structural variants may impact pharmacological activity and safety. Reliable suppliers with validated manufacturing processes and comprehensive quality documentation are recommended to support research and formulation efforts.
Identification & chemistry
| Generic name | Ocinaplon |
|---|---|
| Molecule type | Small molecule |
| CAS | 96604-21-6 |
| UNII | 2H6KVC5E76 |
| DrugBank ID | DB06529 |
Formulation & handling
- Ocinaplon is a small molecule with moderate lipophilicity (LogP 1.63) and low aqueous solubility, indicating formulation challenges for oral bioavailability.
- Its solid state and chemical stability suggest standard handling procedures without special moisture or light sensitivity requirements.
- The compound is intended for oral administration, with no peptide or biologic characteristics affecting formulation strategies.
Regulatory status
Ocinaplon is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
